Jasper Therapeutics, Inc.
A clinical-stage biotech developing therapies targeting mast and hematopoietic stem cells.
JSPR | US
Overview
Corporate Details
- ISIN(s):
- US4718712023 (+3 more)
- LEI:
- Country:
- United States of America
- Address:
- 2200 BRIDGE PKWY SUITE #102, 94065 REDWOOD CITY
- Website:
- https://jaspertx.com/
Description
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company that develops therapies targeting mast and hematopoietic stem cells. The company's lead product candidate is briquilimab, a monoclonal antibody that targets c-Kit (CD117). This therapeutic is designed to deplete mast cells for the treatment of chronic immunological and inflammatory diseases. Jasper Therapeutics is conducting clinical studies to evaluate briquilimab in patients with chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and allergic asthma. The company's mission is to provide safer and more effective therapies for patients with chronic mast cell-driven diseases.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Jasper Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Jasper Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Jasper Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
